Skip to content

Partially randomised preference trial of fire needle treatment of chronic eczema based on real world study

Partially randomised preference trial of fire needle treatment of chronic eczema based on real world study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006602
Enrollment
Unknown
Registered
2022-09-15
Start date
2022-09-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Eczema

Interventions

Patients with a preference for control group:Halometasine Scream
Patients randomised to control group:Halometasine Scream
Patients randomised to fire-needling group:Fire-Needling
Patients with a preference for fire-needling group:Fire-Needling

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?It meets the diagnostic criteria for eczema; ?The course of the disease is more than 3 months, recurrent attacks, and patients with chronic eczema; ?Aged between 18-80; ?No treatment with corticosteroids, antihistamines or immunosuppressants and other topical drugs in the 2 weeks before treatment; ?Voluntarily participate in clinical research and sign an informed notice to cooperate with treatment and follow-up;

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Complicated by severe organic lesions, hematopoietic system and immune system diseases; (3) Eczema occurs on the face or external genitalia and perianal region; (4) The patient has mental illness and does not cooperate with the treatment.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;Eczema Area and Severity Index;

Secondary

MeasureTime frame
IgE,TNF-a,IL-4 of Serum;Patient Satisfaction;Recurrence Time and Frequency;

Countries

China

Contacts

Public ContactXingxian Huang
acuhuangsz@qq.com86-13632822278

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026